Coherus Oncology, Inc.
CHRS
$0.7472
-$0.0204-2.66%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -13.04% | -25.28% | 8.77% | 28.28% | 23.86% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -13.04% | -25.28% | 8.77% | 28.28% | 23.86% |
| Cost of Revenue | -40.36% | -46.91% | 52.45% | 61.34% | 85.03% |
| Gross Profit | 33.89% | 9.72% | -22.85% | -4.92% | -21.00% |
| SG&A Expenses | -22.30% | -27.07% | -22.54% | -16.46% | -13.97% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -25.82% | -30.51% | -3.48% | -2.10% | -2.79% |
| Operating Income | 41.54% | 37.53% | 17.87% | 26.07% | 23.14% |
| Income Before Tax | 47.19% | 40.23% | 21.21% | 24.04% | 15.04% |
| Income Tax Expenses | -- | -- | 100.00% | -- | -- |
| Earnings from Continuing Operations | 47.10% | 40.14% | 21.07% | 24.18% | 15.18% |
| Earnings from Discontinued Operations | -105.37% | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -120.85% | 111.98% | 99.79% | 88.89% | 78.15% |
| EBIT | 41.54% | 37.53% | 17.87% | 26.07% | 23.14% |
| EBITDA | 42.80% | 39.08% | 19.13% | 26.86% | 23.72% |
| EPS Basic | -62.18% | 110.42% | 99.70% | 90.35% | 79.87% |
| Normalized Basic EPS | -17.94% | -2.75% | 49.97% | 52.31% | 40.21% |
| EPS Diluted | -64.15% | 109.22% | 99.51% | 90.07% | 79.64% |
| Normalized Diluted EPS | -17.94% | -2.75% | 49.97% | 52.31% | 40.21% |
| Average Basic Shares Outstanding | 12.72% | 21.94% | 32.74% | 35.55% | 30.95% |
| Average Diluted Shares Outstanding | 12.72% | 21.94% | 32.74% | 35.55% | 30.95% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |